Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

Launched by CENTRE LEON BERARD · Aug 12, 2019

Keywords

ClinConnect Summary

This clinical trial is investigating whether a medication called regorafenib can help prevent the return of bone sarcomas in patients who have already completed their first treatment. Bone sarcomas are a type of cancer that affects the bones, and this study is specifically looking at various types, including osteosarcoma and Ewing sarcoma. Participants in the trial will be randomly assigned to receive either regorafenib for up to 12 months or a placebo, which is an inactive substance. The goal is to see if regorafenib can improve the length of time patients remain free from the disease.

To be eligible for this trial, patients must be at least 12 years old and have a confirmed diagnosis of a primary bone sarcoma. They should also have completed their initial treatment and be in complete remission or have no evidence of the disease. Participants can expect to attend scheduled visits for treatment and monitoring over the course of the trial. It’s essential to note that patients must agree to use contraception during the study, and they should not have any serious health issues that could affect their ability to participate. This trial is currently recruiting participants, and it offers a chance to contribute to the understanding of new treatments for bone sarcomas.

Gender

ALL

Eligibility criteria

• INCLUSION CRITERIA :
• • I1. Age ≥ 12 years at the day of consenting to the study;
• • I2. Patients must have histologically confirmed diagnosis of primary bone sarcoma including but not limited to: Osteosarcomas, Ewing sarcomas, Chondrosarcomas, Undifferentiated Pleomorphic Sarcomas (UPS), Leiomyosarcomas (LMS) and Angiosarcomas;
• I3. Prior treatment for localized or metastatic disease for bone sarcoma must have been completed, consisting of a standard multimodal treatment based on the histological subtype:
• • For OS, (excepted head and neck localisations), neoadjuvant and/or adjuvant chemotherapy should include methotrexate-based regimen for patients \< 18 years old; patients ≥ 18 years old may have received either methotrexate-based regimen or anthracycline and cisplatin-based regimen For head and neck OS, neoadjuvant and/or adjuvant chemotherapy should include adriamycin, cisplatin or ifosfamide-based regimen.
• • For non-OS, neoadjuvant and/or adjuvant chemotherapy should include adriamycin and/or cisplatin-based regimen.
• • I4. Recovery to NCI-CTCAE v5 Grade 0 or 1 level or recovery to baseline preceding the prior treatment from any previous drug/procedure related toxicity (except alopecia, anaemia, and hypothyroidism);
• • I5. Interval between the last chemotherapy administration and the date of randomisation: at least 4 weeks but no longer than 2 months;
• • I6. Confirmed complete remission or no evidence of disease (for metastatic disease);
• Patients with pulmonary micro nodules can be included provided they do not meet the following criteria:
• • At least one lung nodule of 10mm or more
• • And/or at least two nodules well limited between 6-9mm
• • And/or at least 5 nodules well limited of 5mm or less All the other situations will be considered as doubtful lesions except in case of metastatic disease confirmed during the lung surgery of the residual lung lesions after pre-operative chemotherapy. If no other metastatic localisation is detected at the initial staging, the patient will be considered as localised disease and eligible for randomisation.
• • I7. Life expectancy of greater than 12 months;
• • I8. Karnofsky Performance status ≥70 (patients younger than 18-year old) or ECOG performance status \< 2 (adult patients) ;
• I9. Patients must have adequate bone marrow, renal, and hepatic function, as evidenced by the following within 7 days of study treatment initiation:
• • Absolute neutrophil count ≥ 1.5 Giga/l
• • Platelets ≥ 100 Giga/l
• • Haemoglobin≥ 9 g/dl
• • Serum creatinine ≤ 1.5 x ULN
• • Glomerular filtration rate (GFR) ≥30 ml/min/1.73m2 according to the Modified Diet in Renal Disease (MDRD) abbreviated formula
• • AST and ALT ≤2.5 x ULN ( ≤5.0 × ULN for patients with liver involvement of their cancer)
• • Bilirubin ≤1.5 X ULN
• • Alkaline phosphatase ≤2.5 x ULN (≤5 x ULN in patient with liver involvement of their cancer). If Alkaline phosphatase \> 2.5 ULN, hepatic isoenzymes 5-nucleotidase or GGT tests must be performed; hepatic isoenzymes 5-nucleotidase must be within the normal range and/or GGT \< 1.5 x ULN.
• • Lipase ≤1.5 x ULN
• • Spot urine must not show ≥ 1 "+"protein in urine or the patient will require a repeat urine analysis. If repeat urinalysis shows 1 "+" protein or more, a 24-hour urine collection will be required and must show total protein excretion \<1000 mg/24 hours
• • I10. INR/PTT ≤1.5 x ULN; Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care;
• • I11. Women of childbearing potential and male patients must agree to use adequate contraception (Appendix 4) for the duration of treatment and for 7 months (210 days) in WOCBP or 4 months (120 days) in men sexually active with WOCBP after the last dose of regorafenib;
• • I12. Women of childbearing potential must have a negative serum β-HCG pregnancy test within 7 days prior randomization and/or urine pregnancy test within 48 hours before the first administration of the study treatment;
• • I13. Patients, and their parents when applicable, must sign and date an informed consent document indicating that they have been informed of all the pertinent aspects of the trial prior to enrolment;
• • I14. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures;
• • I15. Patients covered by a medical insurance.
• • I16. Body Surface Area (BSA) ≥ 1.30m² at the time of consenting to the study.
• NON-INCLUSION CRITERIA :
• • E1. Prior treatment with any VEGFR inhibitor (thus, any prior exposure to sunitinib, sorafenib, pazopanib, bevacizumab, or other VEGFR inhibitor);
• • E2. All soft tissue sarcomas (including but not limited to soft tissue osteosarcomas and Ewing soft tissue sarcomas) and chordomas;
• • E3. Prior history of other malignancies other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) within 3 years prior to randomization;
• E4. Cardiovascular dysfunction:
• • Left ventricular ejection fraction (LVEF) \< 50%,
• • Congestive heart failure ≥ New York Heart Association (NYHA) class 2,
• • Myocardial infarction \< 6 months prior to first study drug administration,
• • Cardiac arrhythmias requiring therapy (beta blockers or digoxin are permitted),
• • Unstable (angina symptoms at rest) or new-onset angina within the last 3 months prior to first study drug administration;
• • E5. Uncontrolled hypertension (systolic blood pressure \> 150mmHg or diastolic pressure \> 90 mmHg despite optimal treatment);
• • E6. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within the last 6 months before the first study drug administration;
• • E7. Major surgical procedure, open biopsy or significant traumatic injury within 28 days before the first study drug administration;
• • E8. Ongoing infection \> Grade 2 according to NCI-CTCAE v5;
• • E9. Known history of human immunodeficiency virus (HIV) infection;
• Nota Bene: Subjects with diagnosed human immunodeficiency virus (HIV) are eligible to participate in the study if they meet the following criteria:
• • 1. No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months prior to enrolment;
• • 2. No history of AIDS-defining cancers (e.g. Kaposi's sarcoma, aggressive B-cell lymphoma and invasive cervical cancer);
• • 3. Subjects should be on established anti-retroviral therapy for at least 4 weeks and have an HIV viral load of \< 400 copies/mL prior to enrolment;
• • E10. Active hepatitis B or C or chronic hepatitis B or C requiring treatment with antiviral therapy; Nota Bene: Subjects with a history of hepatitis B or C who have normal alanine aminotransferase (ALT) and are hepatitis B surface antigen negative and/or have undetectable HCV RNA are eligible;
• • E11. Dehydration according to NCI-CTC v5 Grade \>1;
• • E12. Difficulties to swallow oral medication and/or any mal-absorption condition and/or any Gastrointestinal (GI) disease that may significantly alter the absorption of regorafenib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, or small bowel resection);
• • E13. Patients with seizure disorder requiring medication;
• • E14. Concurrent enrolment in another clinical trial in which investigational therapies are administered;
• • E15. Known hypersensitivity to the active substance or to any of the excipients;
• • E16. Pregnant women, women who are likely to become pregnant or are breast-feeding
• • E17. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;
• • E18. Patients with history of non-compliance to medical regimens or unwilling or unable to comply with the protocol;
• • E19. Interstitial lung disease with ongoing signs and symptoms at the time of informed consent;
• • E20. Non-healing wound, non-healing ulcer, or non-healing bone fracture;
• • E21. Patients with evidence or history of any bleeding diathesis, irrespective of severity;
• • E22. Any haemorrhage or bleeding event ≥ CTCAE v5 Grade 3 within 4 weeks prior to the first study drug administration;
• • E23. Clinically significant unrelated systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) that would compromise the patient's ability to tolerate study treatment or would likely interfere with study procedures or results;
• • E24. Patients using prohibited concomitant and/or concurrent medications (see section "Prohibited concomitant/concurrent treatments);
• • E25.Patients under tutorship or curatorship.